Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, highlights that multiple myeloma treatment has become much more tailored and selective, which benefits the patients in the long-run. Techniques such as genetic profiling have allowed for optimization of therapy, which ensures treatment side-effects are reduced. Dr Richardson reflects on the long-term dangers of high dose melphalan therapy and enumerates new therapies for multiple myeloma. Besides the recent approval of 12 new drugs, therapies such as CAR T-cell therapy, bispecific T-cell engagers, antibody-drug conjugates (such as belantamab mafodotin), new antibodies (such as isatuximab) and novel agents (such as iberdomide, a cereblon E3 ligase modulator), seem promising for multiple myeloma patients. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Oncopeptides: service on advisory committees and research funding